• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    How Investors Are Reacting To Amphastar Pharmaceuticals (AMPH) Strong Third Quarter Earnings

    Simply Wall St·11/07/2026 09:32:46
    Listen to the news
    • Amphastar Pharmaceuticals reported Q3 2026 results with sales of US$207.61 million and net income of US$37.76 million, alongside higher basic and diluted earnings per share from continuing operations versus the prior year period.
    • The nine month figures show sales of US$562.68 million and net income of US$74.53 million. This indicates that Amphastar Pharmaceuticals is converting its product mix and cost base into steadier profitability across the year, rather than concentrating performance in a single quarter.
    • We will now review how this third quarter earnings performance from Amphastar Pharmaceuticals might influence the existing investment narrative.

    Scan beyond Amphastar Pharmaceuticals and compare this earnings story with a curated 19 high quality undiscovered gems that are also quietly turning steady operations into growing profit potential.

    Amphastar Pharmaceuticals Investment Narrative Recap

    To own Amphastar Pharmaceuticals, you need to be comfortable with a story built on respiratory products, emergency injectables and a pipeline that aims to justify recent capacity and R&D spend. The Q3 2026 report, which shows higher sales and net income versus a year ago, supports the idea that current operations are holding up.

    The short term swing factor is how pricing pressure in glucagon, epinephrine and BAQSIMI rebates interacts with this product mix. The latest quarter does not remove that risk. It indicates that Amphastar Pharmaceuticals is currently offsetting some pressure through newer higher margin products and a broader base of inhalation and injectable therapies.

    The most relevant update is the Q3 2026 earnings report itself. Sales of US$207.61 million and net income of US$37.76 million for the quarter, along with higher basic and diluted EPS from continuing operations versus a year ago, provide a clearer read on execution while the firm scales newer drugs.

    For the nine months to September 30, 2026, Amphastar Pharmaceuticals reported sales of US$562.68 million and net income of US$74.53 million. That profile matters for the main catalyst. The key question is whether recent capital spending and the evolving mix in respiratory and injectable products can comfortably cover higher fixed costs and debt while the pipeline, including future biosimilars, moves closer to commercialization.

    Amphastar Pharmaceuticals' current analyst narrative points to revenue of US$839.3 million and earnings of US$112.6 million by 2029, based on assumed 4.8% yearly revenue growth and an earnings increase of about US$34.1 million from US$78.5 million today.

    Uncover why Amphastar Pharmaceuticals' fair value signals a 21% potential downside to its current price, which leaves little room for error.

    NasdaqGS:AMPH 1-Year Stock Price Chart
    NasdaqGS:AMPH 1-Year Stock Price Chart

    Exploring Other Perspectives

    One alternative lens for Amphastar Pharmaceuticals focuses on the insulin aspart biosimilar as a future swing factor rather than current pricing pressure. The most optimistic analysts were penciling in revenue of about US$884.1 million and earnings of US$123.3 million by 2029. Those pre earnings call assumptions may shift once this new Q3 report is fully reflected.

    Explore 4 other Amphastar Pharmaceuticals fair value estimates, including one that suggests potential upside of as much as 185% from the current price.

    Reach Your Own Conclusion

    Don't just follow the ticker; dig into the data and build a conviction that's truly your own.

    Looking for more Amphastar Pharmaceuticals style investment ideas?

    Once you have taken a view on Amphastar Pharmaceuticals, it can help to line that thesis up against other stocks with clear financial profiles using the Simply Wall St Screener.